Monte Rosa Therapeutics News

Monte Rosa Therapeutics Reports Q1 2024 Financial Results: A Detailed Overview

Yahoo Finance03:26

Buy Rating Affirmed for Monte Rosa Therapeutics Amidst Promising Drug Pipeline and Stable Financials

TipRanksMay 10 17:17

Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026

Monte Rosa Therapeutics Expects Its Cash And Cash Equivalents Of $197.8M To Be Sufficient To Fund Planned Operations And Capital Expenditures Into The First Half Of 2026

BenzingaMay 9 19:54

Monte Rosa Therapeutics Q1 2024 GAAP EPS $(0.53) Beats $(0.59) Estimate

Monte Rosa Therapeutics Q1 2024 GAAP EPS $(0.53) Beats $(0.59) Estimate

BenzingaMay 9 19:53

Monte Rosa Therapeutics | 10-Q: Quarterly report

Futu NewsMay 9 19:47 · Announcements

Monte Rosa Therapeutics Corporate Presentation Release

TipRanksMay 9 19:23

Monte Rosa Therapeutics 1Q Rev $1.06M >GLUE

Monte Rosa Therapeutics 1Q Rev $1.06M >GLUE

Dow JonesMay 9 19:03

Press Release: Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Monte Rosa Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update MRT-2359, a molecular glue degrader (MGD) being developed for MYC-driven solid tumors, advancing i

Dow JonesMay 9 19:00

Monte Rosa Therapeutics Announces Key Management Changes

TipRanksMay 3 04:12

Press Release: Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer

Monte Rosa Therapeutics Announces the Departure of Owen Wallace, Ph.D., Chief Scientific Officer Dr. Wallace will depart his role as CSO effective May 17, 2024, and will serve as a scientific advisor

Dow JonesMay 3 04:01

Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 558.98K in Common Stocks

SEC FILLINGS DISCLOSED/ May 1, $Monte Rosa Therapeutics(GLUE.US)$ Officer Jones Jullian G intends to sell 105.07K shares of its common stock on May 1, with a total market value of approximately $558.9

Futu NewsMay 2 04:31

UBS Adjusts Monte Rosa Therapeutics Price Target to $20 From $22, Maintains Buy Rating

Monte Rosa Therapeutics (GLUE) has an average rating of Buy and price targets ranging from $9 to $22, according to analysts polled by Capital IQ. Price: 5.58, Change: +0.25, Percent Change: +4.60

MT NewswiresApr 29 22:36

Form 144 | Monte Rosa Therapeutics(GLUE.US) Officer Proposes to Sell 813.89K in Common Stocks

SEC FILLINGS DISCLOSED/ Apr 10, $Monte Rosa Therapeutics(GLUE.US)$ Officer Jones Jullian G intends to sell 103.55K shares of its common stock on Apr 10, with a total market value of approximately $813

Futu NewsApr 11 04:30

Monte Rosa Therapeutics (GLUE) Gets a Buy From Piper Sandler

TipRanksApr 9 19:06

Does Monte Rosa Therapeutics (GLUE) Have the Potential to Rally 107.79% as Wall Street Analysts Expect?

Yahoo FinanceApr 4 21:55

Monte Rosa Therapeutics (NASDAQ:GLUE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo

Simply Wall StMar 22 23:49

Analysts Offer Insights on Healthcare Companies: Allogene Therapeutics (ALLO), Moderna (MRNA) and Monte Rosa Therapeutics (GLUE)

TipRanksMar 19 20:11

Monte Rosa Therapeutics Inc (GLUE) Reports Full Year and Q4 2023 Financial Results

Yahoo FinanceMar 16 17:31

Is Monte Rosa Therapeutics (NASDAQ:GLUE) In A Good Position To Invest In Growth?

Yahoo FinanceMar 15 19:09

Wells Fargo Gives a Buy Rating to Monte Rosa Therapeutics (GLUE)

TipRanksMar 15 17:17